Rating Change
Morgan Stanley analysts reiterated a Underweight rating on Veracyte, Inc. (NASDAQ:VCYT) on August 04, 2026.
reiterateNASDAQ:VCYT
Morgan Stanley Reiterates Underweight Rating on Veracyte, Inc. (VCYT)
Rating Change Morgan Stanley analysts reiterated a Underweight rating on Veracyte, Inc. (NASDAQ:VCYT) on August 04, 2026. Market Context Veracyte, Inc.
Market Context
Veracyte, Inc. operates in the Healthcare sector. The stock currently trades at $46.17 with a market capitalization of $3.3B.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Veracyte, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Veracyte, Inc.
Among the 10 most recent ratings: 6 Buy, 2 Hold, 2 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 04, 2026 | Piper Sandler | Overweight | N/A |
| Aug 04, 2026 | Stephens & Co. | Overweight | N/A |
| Aug 04, 2026 | Morgan Stanley | Underweight | N/A |
| Aug 03, 2026 | Canaccord Genuity | Hold | N/A |
| Jul 31, 2026 | Needham | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View VCYT Stock Page
Frequently Asked Questions
What does a Underweight rating mean for VCYT?
A Underweight rating from Morgan Stanley reflects the analyst's outlook on Veracyte, Inc. (NASDAQ:VCYT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the VCYT forecast page.